<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617494</article-id><article-id pub-id-type="pmc">5873770</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Transcatheter Aortic Valve Replacement: The Experience of One
Brazilian Health Care Center</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Azevedo</surname><given-names>Fabiula Schwartz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Correa</surname><given-names>Marcelo Goulart</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Paula</surname><given-names>D&#x000e9;bora Holanda Gon&#x000e7;alves</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Felix</surname><given-names>Alex dos Santos</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Bel&#x000e9;m</surname><given-names>Luciano Herman Jua&#x000e7;aba</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Mendes</surname><given-names>Ana Paula Chedid</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Valeria Gon&#x000e7;alves</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>Bruno Miranda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>Andrey Jos&#x000e9; de Oliveira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Weksler</surname><given-names>Clara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Colafranceschi</surname><given-names>Alexandre Siciliano</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Kasal</surname><given-names>Daniel Arthur Barata</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label> Instituto Nacional de Cardiologia (INC), Rio de Janeiro, RJ,
Brazil. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Fabiula Schwartz Azevedo, Instituto
Nacional de Cardiologia - Cirurgia Cardiovascular, Rua das Laranjeiras, 347 -
Laranjeiras - Rio de Janeiro, RJ, Brazil, Zip code: 22240-006. E-mail:
<email>fabiulaschwartz@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><history><date date-type="received"><day>10</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>Transcatheter aortic valve replacement has been an alternative to invasive
treatment for symptomatic severe aortic stenosis in high risk patients. The
primary endpoint was 30-day and 1-year mortality from any cause. Secondary
endpoints were to compare the clinical and echocardiographic variation
pre-and post- transcatheter aortic valve replacement, and the occurrence of
complications throughout a 4-year follow-up period.</p></sec><sec><title>Methods</title><p>This prospective cohort, nestled to a multicenter study (Registro Brasileiro
de Implante de Biopr&#x000f3;tese por Cateter), describes the experience of a
public tertiary center in transcatheter aortic valve replacement. All
patients who underwent this procedure between October 2011 and February 2016
were included.</p></sec><sec><title>Results</title><p>Fifty-eight patients underwent transcatheter aortic valve replacement. The
30-day all-cause mortality was 5.2% (n=3) and after 1 year was 17.2% (n=10).
A significant improvement in New York Heart Association functional
classification was observed when comparing pre-and post- transcatheter
aortic valve replacement (III or IV 84.4% <italic>versus</italic> 5.8%;
<italic>P</italic>&#x0003c;0.001). A decline in peak was observed
(<italic>P</italic>&#x0003c;0.001) and mean (<italic>P</italic>&#x0003c;0.001)
systolic transaortic gradient. The results of peak and mean post-implant
transaortic gradient were sustained after one year (<italic>P</italic>=0.29
and <italic>P</italic>=0.36, respectively). Left ventricular ejection
fraction did not change significantly during follow-up
(<italic>P</italic>=0.41). The most frequent complications were bleeding
(28.9%), the need for permanent pacemaker (27.6%) and acute renal injury
(20.6%).</p></sec><sec><title>Conclusion</title><p>Mortality and complications in this study were consistent with worldwide
experience. Transcatheter aortic valve replacement had positive clinical and
hemodynamic results, when comparing pre-and post-procedure, and the
hemodynamic profile of the prosthesis was sustained throughout
follow-up.</p></sec></abstract><kwd-group><kwd>Transcatheter Aortic Valve Replacement</kwd><kwd>Heart Valve Prosthesis Implantation</kwd><kwd>Aortic Valve Stenosis/surgery</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BNP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Brain natriuretic
peptide</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EuroSCORE I</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= European System for
Cardiac Operative Risk Evaluation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Functional
classification</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVED</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle
end-diastolic diameter</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transcatheter aortic
valve replacement</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TEE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transesophageal
echocardiogram</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TTE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transthoracic
echocardiogram</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VARC-2</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Valve Academic Research
Consortium-2</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Symptomatic patients with severe aortic stenosis have limited functionality and
survival. For these patients, valve replacement is the treatment of choice. However,
the treatment for those with high or prohibitive surgical risk was restricted to
medication, as in pre-surgery era. After the advent of transcatheter aortic valve
replacement (TAVR) in 2002, symptomatic patients with severe aortic stenosis and
high risk have an alternative intervention option, with survival and functional
improvement. Its use is nowadays spread worldwide, including in developing
countries<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The TAVR experience of
public tertiary health care center was described in this prospective cohort.</p><p>The primary endpoint was a 1-year mortality due to any cause. Secondary endpoints
were to compare functional classification (FC), peak and mean transaortic systolic
gradient and left ventricular ejection fraction (LVEF), when comparing before and
after the procedure. In addition, the present study aimed to evaluate the
complications related to the procedure.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a prospective cohort nestled to a multicenter national study (Registro
Brasileiro de Implante de Biopr&#x000f3;tese por Cateter)<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. The patients included
underwent TAVR between December 2011 and January 2016, at a Brazilian public
tertiary health care center.</p><p>The patient selection protocol started with individuals with severe aortic stenosis
or dysfunctional biologic aortic valve being evaluated by a multidisciplinary team
(formed by cardiologists, cardiac surgeons and nurses). TAVR was considered as
treatment when they presented high or prohibitive surgical risk.</p><p>The TAVR was indicated when at least one of the following criteria was present:
A-patients were considered as high risk, with European System for Cardiac Operative
Risk Evaluation (EuroSCORE I) equal or higher than 15%; or B-the presence of frailty
(identified using subjective criteria by the TAVR team, as difficulty in walking and
low body weight)<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>;
or C-porcelain aorta (circumferential calcification of ascending aorta, as seen on
computer tomography images) was considered as prohibitive risk for conventional
valve replacement surgery.</p><p>Eligible patients were evaluated according to New York Heart Association FC, and
laboratory parameters before the TAVR procedure. The exams included blood analysis
(hemoglobin, creatinine, platelets, brain natriuretic peptide (BNP),
electrocardiogram, transthoracic echocardiogram (TTE) and coronariography. Peak and
mean transaortic gradients, presence of aortic regurgitation, aortic valve area,
left ventricle end-diastolic diameter (LVED) and LVEF (Teicholz method) were
evaluated according to American Echocardiography Society<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>All patients were studied before TAVR by angiotomography images of total aorta,
subclavian, femoral and iliac arteries, in order to evaluate eligibility and to
choose the site of catheter insertion (femoral, transapical or other), the valve
model and size. Exclusion criteria were incompatible size between available
prosthesis and the valve ring size (according to angiotomography images), the
presence of clot in the ventricle, LVEF &#x0003c; 20% on TTE or estimated survival less
than one year.</p><p>The valve models used were those available at the time of initial evaluation. The
valve size was chosen according to valve ring size on angiotomography. Femoral
artery was the preferential access. If not possible, an alternative access was
obtained. TAVR was performed under general anesthesia or sedation anesthesia, and
accompanied by transesophageal echocardiogram (TEE).</p><p>TAVR to treat a dysfunctional biologic prosthetic aortic valve, was called as
valve-in-valve procedure and was performed under the same criteria as listed
above.</p><p>After TAVR procedure, laboratory data was collected in the first 72 hours,
electrocardiogram was performed daily, and one TTE was obtained before patient
discharge, until 7 days after the procedure.</p><p>Functional classification, electrocardiogram and TTE were registered in 30 days, six
months, one year and two years after TAVR.</p><p>Complications were registered as Valve Academic Research Consortium-2 (VARC-2)
definitions<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, as the mortality causes classification. Non identified
cause was considered as cardiovascular cause.</p><sec><title>Statistical Analysis</title><p>Kolmogorov-Smirnov and Shapiro-Wilk tests were used to check distribution
pattern. Continuous variables with normal distribution were presented as mean
&#x000b1; standard deviation, otherwise were presented as median and
interquartile range and were submitted to Student t test or Mann-Whitney.
Categorical variables were presented as frequencies (number, percentage and
confidence interval) and compared through the chi-square and Fisher exact test.
Friedman and Cochran Q were used for paired tests and ANOVA to repeated
measures. Kaplan Meier survival curve estimated the survival rate free of events
in this population and its censored cases were deaths or the last follow-up.
Data were analyzed with the R<sup>&#x000ae;</sup> software 3.1.0 through
Extension EZR 1.27 do R Commander 2.1-4. It was assumed 5% alpha error and
<italic>P</italic> values &#x02264; 0.05 were considered significant. This
study was registered in the local Research Ethics Committee, according to the
Declaration of Helsinki. All participants signed a consent form.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Fifty-eight patients were treated with TAVR. Baseline characteristics are presented
in <xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t2">2</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline clinical profile.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Population (n=58)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age in years, mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">77.8&#x000b1;8.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Age &#x02265; 80 years, n (%)</td><td align="center" rowspan="1" colspan="1">29 (50)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, n (%)</td><td align="center" rowspan="1" colspan="1">36 (62.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>), mean &#x000b1;
SD</td><td align="center" rowspan="1" colspan="1">25.9&#x000b1;5.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Functional classification II (NYHA), n (%)</td><td align="center" rowspan="1" colspan="1">9 (15.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Functional classification III or IV (NYHA), n (%)</td><td align="center" rowspan="1" colspan="1">49 (84.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Syncope, n (%)</td><td align="center" rowspan="1" colspan="1">18 (31.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina, n (%)</td><td align="center" rowspan="1" colspan="1">23 (39.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atherosclerotic coronary disease, n (%)</td><td align="center" rowspan="1" colspan="1">33 (56.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">High blood pressure, n (%)</td><td align="center" rowspan="1" colspan="1">54 (93.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, n (%)</td><td align="center" rowspan="1" colspan="1">14 (24.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia, n (%)</td><td align="center" rowspan="1" colspan="1">38 (65.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior myocardial infarction, n (%)</td><td align="center" rowspan="1" colspan="1">9 (15.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior stroke or transient ischemic attack, n (%)</td><td align="center" rowspan="1" colspan="1">8 (13.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">High pulmonary pressure, n (%)</td><td align="center" rowspan="1" colspan="1">11 (19.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Carotid artery stenosis, n (%)</td><td align="center" rowspan="1" colspan="1">15 (25.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral artery disease, n (%)</td><td align="center" rowspan="1" colspan="1">11 (19.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease, n (%)</td><td align="center" rowspan="1" colspan="1">11 (19.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic aneurysm, n (%)</td><td align="center" rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Porcelain aorta, n (%)</td><td align="center" rowspan="1" colspan="1">24 (41.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematological disorders, n (%)</td><td align="center" rowspan="1" colspan="1">18 (31.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic kidney disease, n (%)</td><td align="center" rowspan="1" colspan="1">42 (72.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine clearance<xref ref-type="table-fn" rid="TFN2">*</xref> (mL/min), median [IQR]</td><td align="center" rowspan="1" colspan="1">47.8 [38.5 - 60.9]</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior coronary artery bypass graft, n (%)</td><td align="center" rowspan="1" colspan="1">10 (17.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior aortic valve replacement, n (%)</td><td align="center" rowspan="1" colspan="1">7 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Percutaneous transluminal coronary angioplasty, n
(%)</td><td align="center" rowspan="1" colspan="1">13 (22.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysfunctional aortic bioprosthesis, n (%)</td><td align="center" rowspan="1" colspan="1">7 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pacemaker, n (%)</td><td align="center" rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE (%), median [IQR]</td><td align="center" rowspan="1" colspan="1">12.7 [8.0 - 20.8]</td></tr><tr><td align="left" rowspan="1" colspan="1">Sinusal rhythm, n (%)</td><td align="center" rowspan="1" colspan="1">41 (70.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation/flutter, n (%)</td><td align="center" rowspan="1" colspan="1">13 (22.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">First degree atrioventricular block, n (%)</td><td align="center" rowspan="1" colspan="1">10 (17.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Left bundle branch block, n (%)</td><td align="center" rowspan="1" colspan="1">7 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Right bundle branch block, n (%)</td><td align="center" rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Left anterior hemiblock, n (%)</td><td align="center" rowspan="1" colspan="1">4 (6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Right bundle branch block + left anterior hemiblock, n
(%)</td><td align="center" rowspan="1" colspan="1">5 (8.6)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>SD=standard deviation; NYHA=New York Heart Association;</p></fn><fn id="TFN2"><label>(*)</label><p>calculated by Cockcroft-Gault formula; IQR=interquartile range;
EuroSCORE=European System for Cardiac Operative Risk Evaluation</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline and after transcatheter aortic valve replacement echocardiogram
values.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Variable</th><th align="center" colspan="2" rowspan="1">Baseline</th><th align="center" colspan="2" rowspan="1">After TAVR<xref ref-type="table-fn" rid="TFN3">*</xref></th></tr><tr><th align="center" rowspan="1" colspan="1">Total<xref ref-type="table-fn" rid="TFN4">**</xref></th><th align="center" rowspan="1" colspan="1">Value</th><th align="center" rowspan="1" colspan="1">Total<xref ref-type="table-fn" rid="TFN4">**</xref></th><th align="center" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LVEF (%), mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">57.4&#x000b1;16</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">59.2&#x000b1;16.4</td></tr><tr><td align="left" rowspan="1" colspan="1">LVED (mm), median [IQR]</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">52.2 (12.6)</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Transaortic peak gradient (mmHg), mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">79.8&#x000b1;22.2</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">20 [16.5-28]</td></tr><tr><td align="left" rowspan="1" colspan="1">Transaortic mean gradient (mmHg), mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">49.3&#x000b1;15</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">10 [8-14]</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic valvular area (cm<sup>2</sup>), mean &#x000b1;
SD</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0.59&#x000b1;0.19</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe or moderate aortic regurgitation, n (%)</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">12 (20.7)</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">13 (22.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb (mg/dL), mean &#x000b1; SD</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">11.6 (1.5)</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">9.4&#x000b1;1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">CR (mg/dL), median [IQR]</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.9 [0.8-1.3]</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">1.1 [0.9-1.4]</td></tr><tr><td align="left" rowspan="1" colspan="1">PLT (x10<sup>3</sup>), median [IQR]</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">183.5 [146.2-224.7]</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">133 [109-179]</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP (pg/mL)</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">316 [125.4 - 906.8]</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p>Before hospital discharge;</p></fn><fn id="TFN4"><label>**</label><p>Total analyzed &#x0003c; 58 = data not available TAVR=Transcatheter aortic
valve replacement; LVEF=left ventricle ejection fraction; SD= standard
deviation; LVED=left ventricle end-diastolic diameter; IQR=interquartile
range; NA=data not available; Hb=hemoglobin; CR=creatinine;
PLT=platelets; BNP=Brain natriuretic peptide</p></fn></table-wrap-foot></table-wrap><p>General anesthesia was employed in 51 (87.9%) cases. Sedation and local anesthesia
were performed in 7 (12.1%) patients and TEE in 53 (91.4%) procedures. The main
access was transfemoral (n=47; 81%). The alternative access used were transapical
(n=7; 12.1%), transaortic (n=3; 5.2%), and subclavian artery (n=1; 1.7%).
Self-expandable valve CoreValve<sup>&#x000ae;</sup> (Medtronic Inc., Minneapolis, MN,
USA) was implanted in 40 (68.9%) patients, balloon-expandable valve
SAPIEN-XT<sup>&#x000ae;</sup> (Edwards Lifesciences, Irvine, CA, USA) in 11 (19%)
and Inovare<sup>&#x000ae;</sup> (Braile Biomedica, S&#x000e3;o Jos&#x000e9; do Rio
Preto, SP, Brazil) in seven (12.1%) cases.</p><p>Seven (12.1%) patients had dysfunctional biological aortic prosthesis and the
procedures were valve-in-valve. All of them had an Inovare<sup>&#x000ae;</sup> model
implanted surgically via transapical access. Echocardiographic and laboratory data
after TAVR are shown in <xref ref-type="table" rid="t2">Table 2</xref>.</p><p>In this cohort, the all-cause mortality was 17.2% (n=10) within the follow-up of 1
year. The mortality within 30 days was 5.2% (n=3) and was considered related to the
procedure. Two of them had apical access: their mortality causes were due to life
threatening bleeding for both, beside major ischemic stroke for one of them. The
third patient that immediately died after the procedure, had atrioventricular block
due to contiguous complication.</p><p>The late mortality occurred in seven cases, five of them related to cardiovascular
causes and the others related to noncardiovascular causes. Among the cardiovascular
causes were: one had major ischemic stroke; three of them had sudden death or
non-identified cause; and one death was related to the procedure (prosthesis
migration and major bleeding). The noncardiovascular related causes were sepsis and
rupture of preexistent esophageal varices.</p><p>Among the patients that died (n=10), three had moderate or severe aortic
regurgitation on the echocardiogram (until seven days after TAVR). They died, each
one, 10.7 and 6.5 months (moderate regurgitation) and 1.5 month (severe
regurgitation) after the procedure.</p><p>Apical access was used to treat dysfunctional bioprosthesis: seven valve-in-valve
procedures, all of them using Inovare<sup>&#x000ae;</sup> model. Among these
subgroup, two early deaths were registered (within the first day after TAVR). Both
had life threatening bleeding, renal injury and received second valve during the
procedure, due to related first valve failure. The first patient had also
ventricular perforation and atrioventricular block. The second had also left bundle
block and major ischemic stroke. One patient died after the 30<sup>th</sup> day
(late mortality) related to a noncardiovascular cause. The other four valve-in-valve
patients did not have any complications.</p><p>Survival analysis is represented by Kaplan Meier curve in <xref ref-type="fig" rid="f1">Figure 1</xref>. Mean follow-up time was 6.4 [1.55-12.9]
months and maximum 33.8 months in this cohort.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Kaplan-Meier survival curve*.</p><p>95% CI - - - - - - Survive ____ + Censored (*) Censored cases represent
last follow-up visit.</p></caption><graphic xlink:href="rbccv-33-01-0001-g01"/></fig>
</p><p>Clinical evolution of FC is presented in <xref ref-type="fig" rid="f2">Figure
2</xref>. The prevalence of FC III or IV pre-TAVR was 84.5% (n=49 of 58)
compared to 30 days that was 14.8% (n=8 of 54; <italic>P</italic>&#x0003c;0.001), six
months 9.1% (n=4 of 44; <italic>P</italic>&#x0003c;0.001); one year 10.8% (n=4 of 37;
<italic>P</italic>&#x0003c;0.001); and two years 10.5% (n=2 of 19;
<italic>P</italic>&#x0003c;0.001).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>New York Heart Association functional classification during follow-up
after transcatheter aortic valve replacement*.</p><p>* Losses were due to deaths or the last follow-up in timeline.</p></caption><graphic xlink:href="rbccv-33-01-0001-g02"/></fig>
</p><p>Echocardiographic evolution by transaortic gradient and LVEF analysis before and
after TAVR are shown in <xref ref-type="fig" rid="f3">Figure 3</xref>. Complications
are presented in <xref ref-type="table" rid="t3">Table 3</xref>.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Left ventricular ejection fraction, transaortic peak, and mean gradient
evolution (mmHg).</p><p>LVEF=Left ventricle ejection fraction; Transaortic (*) Peak and (**) mean
gradients variability before and after TAVR, before hospital discharge.
Transaortic (&#x000a7;) mean and (&#x000a7;&#x000a7;) peak gradient after
TAVR</p></caption><graphic xlink:href="rbccv-33-01-0001-g03"/></fig>
</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Complications during the 4-year follow-up period according to Valve Academic
Research Consortium-2.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="70%" span="1"/><col width="30%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Stroke, n (%)</td><td align="center" rowspan="1" colspan="1">4 (6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction, n (%)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic complications, n (%)</td><td align="center" rowspan="1" colspan="1">17 (29.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Minor bleeding, n (%)</td><td align="center" rowspan="1" colspan="1">7 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Major bleeding, n (%)</td><td align="center" rowspan="1" colspan="1">4 (6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Life threatening bleeding, n (%)</td><td align="center" rowspan="1" colspan="1">6 (10.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular complication, n (%)</td><td align="center" rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Minor vascular complication, n (%)</td><td align="center" rowspan="1" colspan="1">3 (5.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Major vascular complication, n (%)</td><td align="center" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute kidney injury, n (%)</td><td align="center" rowspan="1" colspan="1">12 (20.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage 1, n (%)</td><td align="center" rowspan="1" colspan="1">5 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage 2, n (%)</td><td align="center" rowspan="1" colspan="1">3 (5.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage 3, n (%)</td><td align="center" rowspan="1" colspan="1">2 (3.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pacemaker, n (%)</td><td align="center" rowspan="1" colspan="1">16 (27.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Periprosthetic regurgitation &#x02265; moderate, n
(%)</td><td align="center" rowspan="1" colspan="1">8 (14.8)<xref ref-type="table-fn" rid="TFN5">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Second prosthesis implantation, n (%)</td><td align="center" rowspan="1" colspan="1">7 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular mortality, n (%)</td><td align="center" rowspan="1" colspan="1">8 (13.8)</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>*</label><p>This data was analyzed from available echocardiogram data after TAVR
(until seven days after the procedure) of 54 patients.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This prospective cohort describes the experience of a public tertiary center in
TAVR.</p><p>The small population and the single center analysis are limitations of this study.
Frailty was considered according to subjective impressions of a multidisciplinary
team and may interfere on the reproducibility of selection criteria.</p><p>Mean age in this cohort was similar to main published registries. Mean EuroSCORE was
inferior comparing to previous studies. However, porcelain aorta was more prevalent
in this population<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r9" ref-type="bibr">9</xref>]</sup>. As porcelain aorta is a
formal surgery contraindication and it could have impacted on EuroSCORE profile of
this population<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>General anesthesia was preferred over sedation and local anesthesia. Although recent
published studies reveal the opposite, this scenario is similar to publications of
initial experiences<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>As published in Brazilian<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> and international literature<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>, transfemoral was the main used access. Apical
access was used in all valve-in-valve procedure (seven cases) and contributed 20%
(two cases) to all-mortality in this cohort.</p><p>In cases of dysfunctional aortic bioprosthesis, conventional valve replacement is
associated with higher risk compared to the first cardiac surgery and may
contraindicate the surgery intervention<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Valve-in-valve has shown as a safe alternative and
has shown adequate hemodynamic performance<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>.
In this cohort, valve-in-valve procedures were not analyzed apart and can interfere
on results, mainly on transaortic gradients.</p><p>Mortality was consistent with literature. Brazilian registry<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> had 30 days and one year
mortality of 9.1% and 21.5%, respectively. Data presented in SOURCE
registry<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>
was 6.3% e 10.3% (transfemoral and transapical access, respectively); on ADVANCE
trial<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>
was 4.5%; on FRANCE trial<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>, 12.7%; and FRANCE 2 trial<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, 9.7%; survival analysis
after one year in PARTNER registry<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> was 76.9%, in SOURCE<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> was 76.1%, in FRANCE
2<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> 81.6%,
and Figulla et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> showed 75.9%.</p><p>Aortic regurgitation of at least moderate level in this cohort was 14.81%. Although
TEE had been performed during most procedures<sup>[<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>,
these data were not available for analysis. The use of TTE data done until seven
days after the procedure as the first echocardiogram after TAVR can limit
comparisons among other studies echocardiogram data, since TEE or TTE done in the
operating room is the standard in literature. To avoid further data interference,
two cases without echocardiogram data before the discharge were excluded from the
population analyzed.</p><p>Recently, the new generation of the balloon-expandable valve system has shown less
occurrence of aortic regurgitation and pacemaker implantation<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. This cohort had clinical
endpoints and complications defined by VARC-2<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Accordingly, results should be carefully
compared to the literature, since the same criteria and definitions should have been
used for comparisons.</p><p>Hemorrhagic complications and pacemaker implantation were the main complications in
this study. Comparing to literature, hemorrhagic complications were more frequent
and acute renal injury occurrence was less frequent in this cohort, although there
is a large variation of criteria used among different studies. Pacemaker
implantation was similar to the literature, consistent to the registries which
indicate that this complication is more frequent among the self-expandable valve
model CoreValve<sup>&#x000ae;</sup> model<sup>[<xref rid="r24" ref-type="bibr">24</xref>-<xref rid="r26" ref-type="bibr">26</xref>]</sup>. In this
cohort, this model was used in almost 70% of the procedures.</p><p>The post-TAVR echocardiogram (until seven days after the procedure) data were not
available in four patients. Two of them died during the procedure. The other two had
post-TAVR echocardiogram registries 30 days after the procedure (one with moderate
aortic regurgitation and the other without aortic regurgitation). Thus, among the 54
patients analyzed, one (1.85%) had severe, seven (12.96%) had moderate, twenty-three
(42.59%) had mild and twenty-three (42.59%) did not have aortic regurgitation on the
echocardiogram before hospital discharge.</p><p>Also consistent with literature, significant, lasting clinical and echocardiographic
improvement was registered<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. FC improvement could be seen since the first follow-up
appointment, changing the profile of III and IV predominance to I and II.
Transaortic gradient, peak and mean, fall immediately, maintaining this pattern
during follow-up, as in previous studies<sup>[<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r26" ref-type="bibr">26</xref>]</sup>. LVEF did
not change significantly in this study, however, published studies show improvement
in dilated cardiomyopathy after TAVR<sup>[<xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref>]</sup>.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Mortality and complications in this study were consistent with literature. The more
frequent complications in this cohort were hemorrhagic complications and pacemaker
implantation. TAVR had positive clinical and hemodynamic results for this
population, when comparing pre-and post-procedure. The prosthesis hemodynamic
profile was sustained and LVEF did not change significantly during follow-up.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">FSA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; final approval of
the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MGC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DHGP</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASF</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LHJB</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APCM</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VGS</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AJOM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CW</td><td align="left" valign="top" rowspan="1" colspan="1">Agreement to be accountable for all
aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved; final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ASC</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DABK</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Instituto Nacional de Cardiologia (INC), Rio de
Janeiro, RJ, Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousef</surname><given-names>A</given-names></name><name><surname>Froeschl</surname><given-names>M</given-names></name><name><surname>Hibbert</surname><given-names>B</given-names></name><name><surname>Burwash</surname><given-names>IG</given-names></name><name><surname>Labinaz</surname><given-names>M</given-names></name></person-group><article-title>Transcatheter aortic valve implantation: current and evolving
indications</article-title><source>Can J Cardiol</source><year>2016</year><volume>32</volume><issue>2</issue><fpage>266</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">26481084</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CR</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Miller</surname><given-names>DC</given-names></name><name><surname>Moses</surname><given-names>JW</given-names></name><name><surname>Svensson</surname><given-names>LG</given-names></name><etal/><collab>PARTNER Trial Investigators</collab></person-group><article-title>Transcatheter versus surgical aortic-valve replacement in
high-risk patients</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>23</issue><fpage>2187</fpage><lpage>2198</lpage><pub-id pub-id-type="pmid">21639811</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito</surname><given-names>FS</given-names></name><name><surname>Carvalho</surname><given-names>LA</given-names></name><name><surname>Sarmento-Leite</surname><given-names>R</given-names></name><name><surname>Mangione</surname><given-names>JA</given-names></name><name><surname>Lemos</surname><given-names>P</given-names></name><name><surname>Siciliano</surname><given-names>A</given-names></name><etal/><collab>Brazilian TAVI Registry investigators</collab></person-group><article-title>Outcomes and predictors of mortality after transcatheter aortic
valve implantation: results of the Brazilian registry</article-title><source>Catheter Cardiovasc Interv</source><year>2015</year><volume>85</volume><issue>5</issue><fpage>E153</fpage><lpage>E162</lpage><pub-id pub-id-type="pmid">25510532</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmann</surname><given-names>K</given-names></name><name><surname>Sirotina</surname><given-names>M</given-names></name><name><surname>Rosa</surname><given-names>S</given-names></name><name><surname>Ehrlich</surname><given-names>JR</given-names></name><name><surname>Fox</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>J</given-names></name><etal/></person-group><article-title>The STS score is the strongest predictor of long-term survival
following transcatheter aortic valve implantation, whereas access route
(transapical versus transfemoral) has no predictive value beyond the
periprocedural phase</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2013</year><volume>17</volume><issue>2</issue><fpage>359</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">23644728</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes Jr</surname><given-names>DR</given-names></name><name><surname>Mack</surname><given-names>MJ</given-names></name><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Agnihotri</surname><given-names>A</given-names></name><name><surname>Alexander</surname><given-names>KP</given-names></name><name><surname>Bailey</surname><given-names>SR</given-names></name><etal/><collab>American Heart Association</collab><collab>American Society of Echocardiography</collab><collab>European Association for Cardio-Thoracic Surgery</collab><collab>Heart Failure Society of America</collab><collab>Mended Hearts</collab><collab>Society of Cardiovascular Anesthesiologists</collab><collab>Society of Cardiovascular Computed Tomography</collab><collab>Society for Cardiovascular Magnetic</collab></person-group><article-title>2012 ACCF/AATS/SCAI/STS expert consensus document on
transcatheter aortic valve replacement: developed in collaboration with the
American Heart Association, American Society of Echocardiography, European
Association for Cardio-Thoracic Surgery, Heart Failure Society of America,
Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of
Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic
Resonance</article-title><source>J Thorac Cardiovasc Surg</source><year>2012</year><volume>144</volume><issue>3</issue><fpage>e29</fpage><lpage>e84</lpage><pub-id pub-id-type="pmid">22898522</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Piazza</surname><given-names>N</given-names></name><name><surname>Nikolsky</surname><given-names>E</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Cutlip</surname><given-names>DE</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Standardized endpoint definitions for transcatheter aortic valve
implantation clinical trials: a consensus report from the Valve Academic
Research Consortium</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>2</issue><fpage>205</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">21216739</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltchaninoff</surname><given-names>H</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Gilard</surname><given-names>M</given-names></name><name><surname>Leguerrier</surname><given-names>A</given-names></name><name><surname>Blanchard</surname><given-names>D</given-names></name><name><surname>Fournial</surname><given-names>G</given-names></name><etal/></person-group><article-title>Transcatheter aortic valve implantation: early results of the
FRANCE (FRench Aortic National CoreValve and Edwards)
registry</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>2</issue><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">20843959</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lef&#x000e8;vre</surname><given-names>T</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Wolner</surname><given-names>E</given-names></name><name><surname>Nataf</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Sch&#x000e4;chinger</surname><given-names>V</given-names></name><etal/><collab>PARTNER EU Investigator Group</collab></person-group><article-title>One year follow-up of the multi-centre European PARTNER
transcatheter heart valve study</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>2</issue><fpage>148</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">21075775</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perin</surname><given-names>MA</given-names></name><name><surname>Brito Jr</surname><given-names>FS</given-names></name><name><surname>Almeida</surname><given-names>BO</given-names></name><name><surname>Pereira</surname><given-names>MA</given-names></name><name><surname>Abizaid</surname><given-names>A</given-names></name><name><surname>Tarasoutchi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Percutaneous aortic valve replacement for the treatment of aortic
stenosis: early experience in Brazil</article-title><source>Arq Bras Cardiol</source><year>2009</year><volume>93</volume><issue>3</issue><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">19851659</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayr</surname><given-names>NP</given-names></name><name><surname>Michel</surname><given-names>J</given-names></name><name><surname>Bleiziffer</surname><given-names>S</given-names></name><name><surname>Tassani</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name></person-group><article-title>Sedation or general anesthesia for transcatheter aortic valve
implantation (TAVI)</article-title><source>J Thorac Dis</source><year>2015</year><volume>7</volume><issue>9</issue><fpage>1518</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">26543597</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Chandavimol</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>CR</given-names></name><name><surname>Ricci</surname><given-names>DR</given-names></name><name><surname>Carere</surname><given-names>RG</given-names></name><name><surname>Munt</surname><given-names>BI</given-names></name><etal/></person-group><article-title>Percutaneous aortic valve implantation retrograde from the
femoral artery</article-title><source>Circulation</source><year>2006</year><volume>113</volume><issue>6</issue><fpage>842</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">16461813</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashida</surname><given-names>K</given-names></name><name><surname>Lef&#x000e8;vre</surname><given-names>T</given-names></name><name><surname>Chevalier</surname><given-names>B</given-names></name><name><surname>Hovasse</surname><given-names>T</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Garot</surname><given-names>P</given-names></name><etal/></person-group><article-title>Transfemoral aortic valve implantation new criteria to predict
vascular complications</article-title><source>JACC Cardiovasc Interv</source><year>2011</year><volume>4</volume><issue>8</issue><fpage>851</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">21851897</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaia</surname><given-names>DF</given-names></name><name><surname>Couto</surname><given-names>A</given-names></name><name><surname>Breda</surname><given-names>JR</given-names></name><name><surname>Ferreira</surname><given-names>CB</given-names></name><name><surname>Macedo</surname><given-names>MT</given-names></name><name><surname>Gimenes</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Transcatheter aortic valve-in-valve implantation: a selection
change?</article-title><source>Rev Bras Cir Cardiovasc</source><year>2012</year><volume>27</volume><issue>3</issue><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">23288175</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasic</surname><given-names>M</given-names></name><name><surname>Unbehaun</surname><given-names>A</given-names></name><name><surname>Dreysse</surname><given-names>S</given-names></name><name><surname>Buz</surname><given-names>S</given-names></name><name><surname>Drews</surname><given-names>T</given-names></name><name><surname>Kukucka</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transapical aortic valve implantation after previous aortic valve
replacement: clinical proof of the "valve-in-valve" concept</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>142</volume><issue>2</issue><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">21092989</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaia</surname><given-names>DF</given-names></name><name><surname>Palma</surname><given-names>JH</given-names></name><name><surname>Ferreira</surname><given-names>CBND</given-names></name><name><surname>Souza</surname><given-names>JAM</given-names></name><name><surname>Gimenes</surname><given-names>MV</given-names></name><name><surname>Macedo</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Transcatheter aortic valve implantation: results of the current
development and implantation of a new Brazilian prosthesis</article-title><source>Rev Bras Cir Cardiovasc</source><year>2011</year><volume>26</volume><issue>3</issue><fpage>338</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">22086569</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Schymik</surname><given-names>G</given-names></name><name><surname>Walther</surname><given-names>T</given-names></name><name><surname>Himbert</surname><given-names>D</given-names></name><name><surname>Lef&#x000e8;vre</surname><given-names>T</given-names></name><name><surname>Treede</surname><given-names>H</given-names></name><etal/></person-group><article-title>One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic
Bioprosthesis European Outcome (SOURCE) registry: the European registry of
transcatheter aortic valve implantation using the Edwards SAPIEN
valve</article-title><source>Circulation</source><year>2011</year><volume>124</volume><issue>4</issue><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">21747054</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>S</given-names></name></person-group><source>TAVI registry updates ADVANCE the field, raise hopes for lower stroke
rates</source><date-in-citation content-type="access-date">2017 May 12</date-in-citation><comment>from: <ext-link ext-link-type="uri" xlink:href="http://www.theheart.org/article/1374163.do">http://www.theheart.org/article/1374163.do</ext-link></comment><day>12</day><month>6</month><year>2012</year></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilard</surname><given-names>M</given-names></name><name><surname>Eltchaninoff</surname><given-names>H</given-names></name><name><surname>Iung</surname><given-names>B</given-names></name><name><surname>Donzeau-Gouge</surname><given-names>P</given-names></name><name><surname>Chevreul</surname><given-names>K</given-names></name><name><surname>Fajadet</surname><given-names>J</given-names></name><collab>FRANCE 2 Investigators</collab></person-group><article-title>Registry of transcatheter aortic-valve implantation in high-risk
patients</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>18</issue><fpage>1705</fpage><lpage>1715</lpage><pub-id pub-id-type="pmid">22551129</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figulla</surname><given-names>L</given-names></name><name><surname>Neumann</surname><given-names>A</given-names></name><name><surname>Figulla</surname><given-names>HR</given-names></name><name><surname>Kahlert</surname><given-names>P</given-names></name><name><surname>Erbel</surname><given-names>R</given-names></name><name><surname>Neumann</surname><given-names>T</given-names></name></person-group><article-title>Transcatheter aortic valve implantation: evidence on safety and
efficacy compared with medical therapy. A systematic review of current
literature</article-title><source>Clin Res Cardiol</source><year>2011</year><volume>100</volume><issue>4</issue><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">21165626</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JC</given-names></name><name><surname>Varghese</surname><given-names>V</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Popma</surname><given-names>JJ</given-names></name></person-group><article-title>Transcatheter aortic valve implantation: lessons from the PARTNER
(Placement of Aortic Transcatheter Valves) trial</article-title><source>JACC Cardiovasc Interv</source><year>2011</year><volume>4</volume><issue>1</issue><fpage>132</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">21251642</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Jaegere</surname><given-names>PP</given-names></name><name><surname>Piazza</surname><given-names>N</given-names></name><name><surname>Galema</surname><given-names>TW</given-names></name><name><surname>Otten</surname><given-names>A</given-names></name><name><surname>Soliman</surname><given-names>OI</given-names></name><name><surname>Van Dalen</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Early echocardiographic evaluation following percutaneous
implantation with the self-expanding CoreValve Revalving System aortic valve
bioprosthesis</article-title><source>EuroIntervention</source><year>2008</year><volume>4</volume><issue>3</issue><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">19110809</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zaiping</surname><given-names>J</given-names></name></person-group><article-title>Transcatheter aortic valve implantation with balloon-expandable
valve: early experience from China</article-title><source>Rev Bras Cir Cardiovasc</source><year>2015</year><volume>30</volume><issue>4</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">27163416</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>P</given-names></name><name><surname>Piazza</surname><given-names>N</given-names></name><name><surname>van Mieghem</surname><given-names>NM</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Updated standardized endpoint definitions for transcatheter
aortic valve implantation: the Valve Academic Research Consortium-2
consensus document</article-title><source>J Thorac Cardiovasc Surg</source><year>2013</year><volume>145</volume><issue>1</issue><fpage>6</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">23084102</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athappan</surname><given-names>G</given-names></name><name><surname>Patvardhan</surname><given-names>E</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Svensson</surname><given-names>LG</given-names></name><name><surname>Lemos</surname><given-names>PA</given-names></name><name><surname>Fraccaro</surname><given-names>C</given-names></name><etal/></person-group><article-title>Incidence, predictors, and outcomes of aortic regurgitation after
transcatheter aortic valve replacement: meta-analysis and systematic review
of literature</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>61</volume><issue>15</issue><fpage>1585</fpage><lpage>1595</lpage><pub-id pub-id-type="pmid">23500308</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amabile</surname><given-names>N</given-names></name><name><surname>Azmoun</surname><given-names>A</given-names></name><name><surname>Ghostine</surname><given-names>S</given-names></name><name><surname>Ramadan</surname><given-names>R</given-names></name><name><surname>Haddouche</surname><given-names>Y</given-names></name><name><surname>Raoux</surname><given-names>F</given-names></name><etal/></person-group><article-title>Incidence, predictors and prognostic value of serious hemorrhagic
complications following transcatheter aortic valve
implantation</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><issue>1</issue><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">23079085</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbanti</surname><given-names>M</given-names></name><name><surname>Latib</surname><given-names>A</given-names></name><name><surname>Sgroi</surname><given-names>C</given-names></name><name><surname>Fiorina</surname><given-names>C</given-names></name><name><surname>De Carlo</surname><given-names>M</given-names></name><name><surname>Bedogni</surname><given-names>F</given-names></name><etal/></person-group><article-title>Acute kidney injury after transcatheter aortic valve implantation
with self-expanding CoreValve prosthesis: results from a large multicentre
Italian research project</article-title><source>EuroIntervention</source><year>2014</year><volume>10</volume><issue>1</issue><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">24213329</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000e9;n&#x000e9;reux</surname><given-names>P</given-names></name><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>Van Mieghem</surname><given-names>NM</given-names></name><name><surname>Kodali</surname><given-names>S</given-names></name><name><surname>Kirtane</surname><given-names>AJ</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><etal/></person-group><article-title>Clinical outcomes after transcatheter aortic valve replacement
using valve academic research consortium definitions: a weighted
meta-analysis of 3,519 patients from 16 studies</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><issue>25</issue><fpage>2317</fpage><lpage>2326</lpage><pub-id pub-id-type="pmid">22503058</pub-id></element-citation></ref></ref-list></back></article>